Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-CURE: Adjuvant atezolizumab in resected PD-L1 positive NSCLC (Japan, observational)
jRCT1031220647Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: 3-year disease-free survival rate. Started Apr 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031220647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220647.